Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Top Healthcare Picks: Precision BioSciences (DTIL), Sarepta Therapeutics (SRPT)

Tipranks - Tipranks - Fri Apr 24, 11:06AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Precision BioSciences (DTIL), Sarepta Therapeutics (SRPT) and Gilead Sciences (GILD) with bullish sentiments.

Claim 30% Off TipRanks

Precision BioSciences (DTIL)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Precision BioSciences, with a price target of $60.00. The company’s shares closed last Thursday at $7.55.

According to TipRanks.com, Trucchio is a 5-star analyst with an average return of 30.0% and a 54.0% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Arrowhead Pharmaceuticals, and Alto Neuroscience, Inc. ;'>

Currently, the analyst consensus on Precision BioSciences is a Strong Buy with an average price target of $36.33, a 359.3% upside from current levels. In a report issued on April 16, JonesTrading also initiated coverage with a Buy rating on the stock with a $30.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Sarepta Therapeutics (SRPT)

Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics today and set a price target of $31.00. The company’s shares closed last Thursday at $20.28.

According to TipRanks.com, Ear is a 2-star analyst with an average return of 0.0% and a 38.4% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Cartesian Therapeutics. ;'>

Currently, the analyst consensus on Sarepta Therapeutics is a Hold with an average price target of $21.10, implying a 3.4% upside from current levels. In a report issued on April 17, Wedbush also maintained a Buy rating on the stock with a $35.00 price target.

Gilead Sciences (GILD)

In a report released today, Umer Raffat from Evercore ISI maintained a Buy rating on Gilead Sciences. The company’s shares closed last Thursday at $132.94.

According to TipRanks.com, Raffat is a 4-star analyst with an average return of 8.2% and a 48.9% success rate. Raffat covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, Atea Pharmaceuticals, and Spyre Therapeutics. ;'>

Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $159.47, implying a 19.0% upside from current levels. In a report issued on April 8, Needham also maintained a Buy rating on the stock with a $170.00 price target.

Read More on DTIL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).